Laura Kresty, Ph.D., M.S., is an Associate Professor of Surgery at the University of Michigan in the Section of Thoracic Surgery. Dr. Kresty earned her M.S. in Public Health in 1995 and completed her PhD in Public Health from The Ohio State University in 2000, with a major in Cancer Chemoprevention and Epidemiology and a minor in Health Promotion and Disease Prevention. She remained at The Ohio State University to complete a NCI-Sponsored Post-Doctoral Fellowship in Molecular Oncology, followed by a faculty appointment in Internal Medicine. In 2008, Dr. Kresty joined the University of Miami, Miller School of Medicine and Sylvester Cancer where she continued her research focused on the inhibition of aero-digestive tract cancers. Dr. Kresty also served as Director for the Doctorate in Epidemiology Program and was a Cancer Biology Steering Committee Member at the University of Miami. Dr. Kresty joined the Medical College of Wisconsin in 2013 where she conducted research through June of 2017.
Dr. Kresty joined the faculty at the University of Michigan in July of 2017. Her research is focused on evaluating preventive agents and novel strategies for targeting cancers of the esophagus, lung and head and neck. Dr. Kresty’s research includes evaluating the cancer inhibitory potential cranberry proanthocyanidins (C-PAC), the NSAID sulindac alone or in combination with the histamine H2-receptor antagonist ranitidine (Zantac), a phenylbutyrate-derived histone deacetylase inhibitor, a novel mitochondrial targeted inhibitor and vitamin D. To assess agent mechanism of action and identify targets standard molecular biology techniques are combined with a battery of high-throughput platforms including proteomics, metabolomics, microbiomics and expression profiling. Potential cancer inhibitors are evaluated utilizing in vitro assays, employing clinically relevant in vivo models, and translating the evaluation of promising agents into early phase trials in high risk human cohorts. Additional research interests include the linkage between dietary fat, obesity and EAC and evaluating detection of early epithelial and sub-epithelial esophageal changes utilizing a novel imaging technology which may improve non-invasive surveillance modalities and permit rapid evaluation of preventive agent efficacy.
Dr. Kresty serves as an Associate Editor for Molecular Carcinogenesis, a Review Editor for The Editorial Board of Clinical Nutrition, a Specialty of Frontiers in Nutrition and is a peer reviewer for multiple journals in her field. She is a Standing Member of the National Cancer Institute’s Chemo/Dietary Prevention Study Section and has served on numerous additional NCI, NIDDK, and NCCAM Special Emphasis Panels and Review Sections since 2009. Dr. Kresty is a member of the Cancer Epidemiology and Prevention Program within the University of Michigan Cancer Center.